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RecurrenceChondroitin sulfate proteoglycan 4 (CSPG4), a transmembrane proteoglycan originally identiﬁed in mel-
anoma cells, has been reported to be expressed in breast cancer cells. This study was performed to exam-
ine the expression and signiﬁcance of CSPG4 in a cohort of breast cancer patients. Immunohistochemical
analysis of CSPG4 was performed on tissue microarrays constructed from tissue specimens from 240
breast cancer patients. CSPG4 staining was correlated with clinical and pathological characteristics, over-
all survival (OS), and disease recurrence. Contradicting to a previous report, our results showed that high
CSPG4 expression was not related to triple-negative status of breast cancer patients. The Kaplan–Meier
method showed that high CSPG4 expression was signiﬁcantly associated with shorter time to recurrence
(TTR). Patients with high CSPG4 expression had poorer OS and shorter TTR in a multivariate survival anal-
ysis after adjustment for stage, tumor grade, expression of estrogen receptor and progesterone receptor,
and HER2 overexpression. This study showed that high CSPG4 expression correlates with disease recur-
rence and OS in breast cancers.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction melanoma cells [9]. CSPG4 plays an important role in growth,Breast cancer is a highly heterogeneous disease in terms of mor-
phology, molecular characteristics, and response to treatment.
Molecular proﬁling studies have provided a glimpse of the com-
plexity and underlying genetic signature of breast cancer [1–3].
Several molecular subgroups have been proposed with the aid of
DNA microarray: luminal A, luminal B, human epidermal growth
factor receptor 2 (HER2), normal, and basal-like [1–3]. Immunohis-
tochemical proﬁling based on expression of estrogen receptor (ER),
progesterone receptor (PR), and HER2 approximate the molecular
taxonomy of breast cancer patients and provided prognostic infor-
mation and basis for treatment options [4–8].
Chondroitin sulfate proteoglycan 4 (CSPG4), also known as NG2,
is a transmembrane proteoglycan highly expressed in humanmotility, and survival of melanoma cells [10–12]. In breast cancer,
CSPG4 has been found to be highly expressed on aggressive breast
cancer cell lines and contributed to the P-selectin binding that
potentiates the metastatic spread of breast cancer [13]. CSPG4
has also been reported to be expressed in primary triple-negative
breast cancer (TNBC), the subset of breast cancer that lacks the
immunohistochemical expression of ER, PR, and HER2, lesions
and TNBC cell lines, and may be a therapeutic target for mAb-based
immunotherapy in breast tumors with TNBC phenotype [14].
However, the frequency and clinical signiﬁcance of CSPG4 in breast
cancer has yet to be determined. The objectives of the present
study included identiﬁcation of breast tumors exhibiting the
CSPG4 phenotype, as well as assessment of CSPG4 expression in
relation to prognosis and various clinical and pathological features.2. Materials and methods
2.1. Breast tissue microarray
Our study cohort was composed of 240 tumor specimens from
breast cancer excisions collected at the time of surgery between
January 2000 and December 2006 at the Department of Surgery,
Table 1
Distribution of the intensity and percentage scores of CSPG4 immunohistochemical
staining of the 240 breast tumors.
Percentage score N
0 1 2 3
Intensity score 0 40 0 0 0 40
1 0 12 60 51 123
2 0 0 11 46 57
3 0 0 2 18 20
N 40 12 73 115 240
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newly diagnosed at the time of specimen collection and have not
yet begun radiotherapy, chemotherapy, or hormonal treatment.
Samples were ﬁxed in 10% neutral buffered formalin and embed-
ded in parafﬁn. Areas of invasive carcinoma were selected and
marked on the hematoxylin and eosin stained slides. The corre-
sponding tissue blocks were sampled for tissue microarray
(TMA). Follow-up information, histopathological and clinical data
including age, sex, tumor size, ER, PR, HER2 overexpression, tumor
grade, stage, recurrence, and survival were obtained from the can-
cer registry and medical charts. The length of follow-up ranged
from 1 to 131 months, with a mean of 84 months. This protocol
was approved by the Institutional Review Board of Kaohsiung
Medical University Hospital.
2.2. Immunohistochemistry
The breast TMA was evaluated for CSPG4 expression using
immunohistochemical staining. Brieﬂy, 4-lm-thick sections were
deparafﬁnized in xylene, dehydrated through three alcohol
changes. Endogenous peroxidase activity was quenched with 3%
hydrogen peroxide in methanol. Antigen retrieval was performed
in 96 C solution of 0.01 mol/L sodium citrate buffer (pH 6.0) for
30 min. Slides were then incubated with anti-NG2 mouse mono-
clonal antibody (1:50 dilution, ab83508, Abcam, Cambridge, MA)
for 30 min at room temperature. Human melanoma samples and
an isotype- and concentration-matched nonimmune IgG (Abcam)
were used as positive and negative controls, respectively. Staining
was detected using the EnVision Detection Systems Peroxidase/
DAB, Rabbit/Mouse kit (Dako, Glostrup, Denmark). After visualiza-
tion, the TMA sections were then counterstained with hematoxylin
(MERCK, Darmstadt, Germany). The expression of CSPG4 was eval-
uated for intensity of reactivity and percentage of positive cells.
The intensity was evaluated as 0, 1, 2, and 3 for negative, weak,
moderate, and strong staining, respectively. The percentage of tu-
mor cells showing positive staining was recorded as follows: 0,
staining in <1%; 1, staining in 1–10%; 2, staining in 11–50%; and
3, staining in >50% of tumor cells. The total score, ranged from 0
to 9, was calculated by multiplying the intensity and percentage
scores. The CSPG4 immunoreactivity was assessed independently
by two pathologists scoring coded sections and conﬂicting scores
were resolved at a discussion microscope.
2.3. Statistical analysis
Receiver operating characteristics (ROC) curve analysis was ap-
plied to calculate the expression cut-off value predicting survival
for CSPG4. Expression level of CSPG4 was analyzed with clinical
data to assess for correlation with clinical outcome by Pearson’s
chi-square test. Overall survival (OS) and time to recurrence
(TTR) were estimated by the Kaplan–Meier method and compared
by the log-rank test. OS was deﬁned as the time from diagnosis un-
til the time of death. TTR was deﬁned as the time between date of
diagnosis and date of local recurrence/distant metastasis. Patients
still alive/without evidence of recurrence were censored at last fol-
low-up. The Cox proportional hazards regression model was used
to test the statistical independence and signiﬁcance of CSPG4 in
predicting the risk of death and recurrence. Variables in the model
included tumor grade, stage, ER, PR, and HER2 overexpression. A
p < 0.05 was considered to indicate statistical signiﬁcance.Fig. 1. Representative immunohistochemistry analysis of CSPG4 protein expression
on TMA of breast cancer samples. The breast TMA was stained and scored as
described in materials and methods. (A) Negative CSPG4 expression (score = 0). (B)
Low CSPG4 expression (score = 4). (C) High CSPG4 expression (score = 6).3. Results
Table 1 depicts distribution of the intensity and percentage
scores of CSPG4 immunohistochemical staining of the 240 breasttumor samples examined. A total score was obtained by multiply-
ing the percentage and intensity scores for each sample. A cut-off
value of 6 was established by ROC curve analysis and was used
as the uniform cut-off point for subsequent analyses. High CSPG4
expression, as deﬁned by a score of 6 or greater, was observed in
66 of the 240 (27.5%) breast tumors examined. Fig. 1 shows exam-
ples of cases with high and low CSPG4 expression. Clinical and
pathological characteristics of patients, including triple-negative
status, stratiﬁed by CSPG4 expression level showed that there
was no apparent difference between the two groups (Table 2).
Table 2
Patient clinicopathological characteristics and CSPG4 expression in breast cancer patients.
CSPG4 expression N p
Low (N = 174) High (N = 66)
N % N %
Age, years, mean (SD) 49.6 (11.4) 48.0 (11.1) 240 0.321
ER
Negative 61 37.0 22 33.8 83 0.657
Positive 104 63.0 43 66.2 147
PR
Negative 78 47.9 27 42.9 105 0.500
Positive 85 52.1 36 57.1 121
HER2 overexpression
Negative 107 66.9 38 62.3 145 0.522
Positive 53 33.1 23 37.7 76
Triple negative
No 129 79.6 53 85.5 182 0.315
Yes 33 20.4 9 14.5 42
Lymph node metastasis
No 94 56.3 34 52.3 128 0.584
Yes 73 43.7 31 47.7 104
Grade
I 38 32.2 12 23.1 50 0.480
II 53 44.9 26 50.0 79
III 27 22.9 14 26.9 41
Stage
0 23 13.7 10 15.6 33 0.621
I 33 19.6 9 14.1 42
II 81 48.2 30 46.9 111
III 29 17.3 15 23.44 44
IV 2 1.2 0 0.0 2
Table 3
Multivariate analysis for overall survival and time to recurrence of breast cancer
patients.
Variable OS TTR
HR 95% CI p HR 95% CI p
High CSPG4
expression
2.43 1.17–5.06 0.018 2.69 1.46–4.94 0.001
ER 0.33 0.11–0.96 0.042 0.33 0.14–0.78 0.011
PR 2.04 0.73–5.73 0.174 1.31 0.58–2.93 0.513
HER2 overexpression 1.01 0.47–2.17 0.988 0.88 0.46–1.66 0.684
Stage III, IV 3.89 1.80–8.40 0.001 2.98 1.57–5.64 0.001
Grade III 0.92 0.38–2.24 0.856 0.49 0.22–1.09 0.081
Fig. 2. Kaplan–Meier plots for (A) overall survival and (B) time
516 N.C. Hsu et al. / Biochemical and Biophysical Research Communications 441 (2013) 514–518CSPG4 expression was analyzed for association with OS and
TTR. The multivariate Cox model which isolated the effect of CSPG4
expression on OS from other variables (tumor grade, stage, ER, PR,
and HER2 overexpression) indicated that high CSPG4 expression
was an independent prognostic factor [hazard ratio (HR) = 2.43
(1.17–5.06), p = 0.018]. ER expression [HR = 0.33 (0.11–0.96),
p = 0.042] and stage [HR = 3.89 (1.80–8.40), p = 0.001] were also
independent factors inﬂuencing OS (Table 3). Multivariate analysis
for TTR adjusted for the same variables revealed that high CSPG4
expression [HR = 2.69 (1.46–4.94), p = 0.001] was also signiﬁcant
with regard to disease recurrence. Similarly, ER positivity
[HR = 0.33 (0.14–0.78), p = 0.011] and stage [HR = 2.98 (1.57–
5.64), p = 0.001] also showed a statistically signiﬁcant associationto recurrence for patients according to CSPG4 expression.
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The difference in OS between patients with high CSPG4 expression
and those with negative/low CSPG4 expression was not signiﬁcant
(p = 0.193) (Fig. 2A). However, assessment of recurrence in these
patients revealed that high CSPG4 expression was correlated with
a shorter TTR (p = 0.047) (Fig. 2B).4. Discussion
In breast cancer, CSPG4 has previously been suggested to be
preferentially expressed in primary TNBC lesions in a study involv-
ing immunohistochemical analysis performed on a small set of
samples and without performing statistical analysis [14]. In this
study, we incorporated staining intensity and percentage of immu-
nopositive tumor cells for the scoring of CSPG4 expression and
examined a more diverse set of breast tumors. The results indi-
cated that high CSPG4 expression was not statistically associated
with triple-negative status of breast cancer patients. In the same
study, Wang et al. also reported that CSPG4 is expressed in TNBC
cell lines and used the spontaneous metastatic MDA-MB-435 cells
line as a model of TNBC, and concluded that CSPG4 is a possible
target for immunotherapy of TNBC [14]. The MDA-MB-435 cells
were originally thought to be derived from a breast carcinoma as
part of the MD Anderson series [15]. However, gene expression
microarray proﬁling and immunohistochemistry studies have re-
vealed that these cells originated from melanoma [16–19]. The
MDA-MB-435 cells were found to be identical to the M14 human
melanoma cell line [20] and the American Type Culture Collection
has ofﬁcially declared the MDA-MB-435 cells as melanoma cells.
Thus, the MDA-MB-435 cells are not an acceptable model for TNBC
[21].
Despite a statistically signiﬁcant correlation could not be estab-
lished between high CSPG4 expression and TNBC, the current study
showed that high CSPG4 expression may correlate with disease
recurrence and/or survival in patients with breast cancer. Kap-
lan–Meier analysis indicated that patients with high CSPG4 expres-
sion exhibited signiﬁcant shorter TTR than those with negative/
lower CSPG4 expression (p = 0.047). High CSPG4 expression was
identiﬁed as an independent predictive factor for poor OS
(p = 0.018) and shorter TTR (p = 0.001) when adjusting for various
clinical and pathological parameters of breast cancer in the Cox
regression models. The multivariate analysis also revealed that
ER-positive women were associated with longer OS and TTR. This
ﬁnding is in agreement with the reports that ER-positive tumors
progress more slowly than ER-negative cells and women with
ER-positive cancer currently have more treatment options [22,23].
Various mechanisms of how CSPG4 promotes tumor migration,
metastasis, and chemoresistance have been proposed [12,13,24–
29]. CSPG4-speciﬁc monoclonal antibody has been shown to pro-
duce anti-tumor effects likely via blocking of important migratory,
mitogenic, and survival signaling pathways in tumor cells [30]. The
present study supports an oncogenic role of CSPG4 in breast cancer
[13] and with further validation, CSPG4 may be a promising new
target to implement antibody-based immunotherapy in a subset
of aggressive breast cancers.
The limitation of this study is that it suffered from a limited
sample size. Given the heterogeneity of human breast cancer, a
large sample size can more accurately identify molecular aberra-
tion that could be most associated with clinical features and out-
comes. In conclusion, the present study suggests that high CSPG4
expression is not related to triple-negative status of breast cancer
patients. In agreement with its oncogenic properties, high CSPG4
expression correlates with disease recurrence and OS, and may
serve as a marker for poor outcome and possibly a target for treat-
ment in aggressive breast cancers.Acknowledgments
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